Article

SSRI adverse events: how to monitor and manage.

Department of Psychiatry, University of Florida, Gainesville, FL 32610, USA.
International Review of Psychiatry (Impact Factor: 1.8). 05/2008; 20(2):203-8. DOI: 10.1080/09540260801889211
Source: PubMed

ABSTRACT Antidepressants are efficacious for pediatric major depressive disorder, obsessive compulsive disorder (OCD), and non-OCD anxiety disorders. Antidepressants should be used in an evidence-based fashion, with frequent monitoring for side effects, especially when initiating treatment and adjusting dosage. With diligence to appropriate prescribing and monitoring, the benefits of therapy outweigh the potential of treatment related risk.

0 Followers
 · 
139 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Herbal remedies play an important role in treatment of psychiatric disorders. The aim of this study was to assess the efficacy of crocin, the main active constituent of saffron, as an adjunctive treatment in major depressive disorder (MDD). This study was a randomized, double-blind, placebo-controlled, pilot clinical trial. It was carried out during 4 weeks in two groups (placebo and treatment) on 40 MDD patients between 24 and 50 years old in Ibn-e-Sina psychiatric hospital, Mashhad, Iran, from March 2013 to December 2013. The crocin group (n=20) was given one selective serotonin reuptake inhibitor (SSRI) drug (fluoxetine 20mg/day or sertraline 50mg/day or citalopram 20mg/day) plus crocin tablets (30mg/day; 15mg BID) and placebo group (n=20) was administered one SSRI (fluoxetine 20mg/day or sertraline 50mg/day or citalopram 20mg/day) plus placebo (two placebo tablets per day) for 4 weeks. Both groups filled beck depression inventory (BDI), beck anxiety inventory (BAI), general health questionnaire (GHQ), the mood disorder questionnaire (MDQ), side effect evaluation questionnaire, and demographic questionnaire before and after one month intervention. The crocin group showed significantly improved scores on BDI, BAI and GHQ compared to placebo group (Pvalue<0.0001). The averages of decrease in BDI, BAI and GHQ scores in placebo group were 6.15, 2.6 and 10.3 respectively, whereas the values in crocin group were 17.6, 12.7 and 17.2 after 4 weeks trial. Poor patient compliance with medications and short trial period, small sample size and self-report assessments were the major limitations of this study. These results demonstrated the effect of crocin in depression and could be administered in treatment of MDD patients. Copyright © 2014 Elsevier B.V. All rights reserved.
    Journal of Affective Disorders 11/2014; 174C:51-56. DOI:10.1016/j.jad.2014.11.035 · 3.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mood disorders such as major depressive disorder and bipolar disorder are chronic and recurrent illnesses that cause significant disability and affect approximately 350 million people worldwide. Currently available biogenic amine treatments provide relief for many and yet fail to ameliorate symptoms for others, highlighting the need to diversify the search for new therapeutic strategies. Here we present recent evidence implicating the role of N-methyl-D-aspartate receptor (NMDAR) signaling in the pathophysiology of mood disorders. The possible role of NMDARs in mood disorders has been supported by evidence demonstrating that: (i) both BPD and MDD are characterized by altered levels of central excitatory neurotransmitters; (ii) NMDAR expression, distribution, and function are atypical in patients with mood disorders; (iii) NMDAR modulators show positive therapeutic effects in BPD and MDD patients; and (iv) conventional antidepressants/mood stabilizers can modulate NMDAR function. Taken together, this evidence suggests the NMDAR system holds considerable promise as a therapeutic target for developing next generation drugs that may provide more rapid onset relief of symptoms. Identifying the subcircuits involved in mood and elucidating the role of NMDARs subtypes in specific brain circuits would constitute an important step toward the development of more effective therapies with fewer side effects.
    Neuroscience & Biobehavioral Reviews 09/2014; 47. DOI:10.1016/j.neubiorev.2014.08.017 · 10.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The last two decades have seen an increase in evidence supporting behavioral and pharmacologic treatments of pediatric obsessive-compulsive disorder, a debilitating anxiety disorder that affects about 1% of youth. However, dissemination of knowledge about these treatments to pediatric health care providers and families of affected children has been less successful. Following best practice guidelines, specific evidence for cognitive-behavioral therapy with exposure and response prevention and pharmacotherapy with serotonin reuptake inhibi-tors are presented. A discussion of clinical features and their impact on treatment delivery and empirically based suggestions for overcoming these barriers are also presented. Future directions for enhancing treatment implementation and dissemination are discussed.
    01/2012; DOI:10.2147/PHMT.S23308